Dr. Zheng Gu serves as the Vice President of Pharmacovigilance at AVEO. With a career spanning over 20 years in the pharmaceutical and biotechnology industries, Dr. Gu has extensive experience in Pharmacovigilance with major treatment modalities in Oncology. Dr. Gu has taken leadership roles with increasing responsibilities in Clinical Development, Medical Affairs and Pharmacovigilance both in the United States and internationally. 

Prior to joining AVEO’s management team, Dr. Gu served as Vice President, Head of Global Safety at ADC Therapeutics. Dr. GU has also held positions as Therapeutic Area Safety Head in Oncology at Janssen Pharmaceutical Companies of Johnson & Johnson, Head of Patient Safety in Oncology Hematology at Novartis Pharmaceuticals and Associate Vice President of U.S. Safety at Sanofi-Aventis Pharmaceuticals.  Dr. Gu is a nephrologist by training and obtained her M.D. from Shanghai Jiao Tong University School of Medicine in China.